Patents for A61P 35 - Antineoplastic agents (221,099)
02/2005
02/22/2005US6858222 Fabrication of drug loaded biodegradable polymer fibers
02/22/2005CA2310778C Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
02/22/2005CA2185352C Novel muteins of ifn-.beta.
02/17/2005WO2005014819A1 Esophageal cancer antigen and utilization thereof
02/17/2005WO2005014809A1 Polypeptide specific to liver cancer, polynucleotide encoding the polypeptide and rna molecule inhibiting the expression of the polypeptide
02/17/2005WO2005014777A2 Methods and compositions for increasing the efficacy of biologically-active ingredients
02/17/2005WO2005014647A1 Product and composition containing a concholepas concholepas hemocyanin (cch) subunit a, and a method of use thereof
02/17/2005WO2005014634A1 A gene and uses therefor
02/17/2005WO2005014598A1 Substituted imidazopyrimidines for the prevention and treatment of cancer
02/17/2005WO2005014588A1 Substituted thienyl-hydroxamic acids having histone deacetylase activity
02/17/2005WO2005014584A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparation and use as modulators of apoptosis
02/17/2005WO2005014577A1 Novel farnesyl protein transferase inhibitors as antitumor agents
02/17/2005WO2005014576A1 Isoquinolinone derivative, process for producing the same and use thereof
02/17/2005WO2005014574A1 Substituted lactams and their use as anti-cancer agents
02/17/2005WO2005014572A1 Pyrimidylpyrrole derivatives active as kinase inhibitors
02/17/2005WO2005014567A1 Mycophenolic acid bismuth salt
02/17/2005WO2005014566A1 Benzofuran derivatives useful for treating hyper-proliferative disorders
02/17/2005WO2005014077A2 Catheter balloon systems and methods
02/17/2005WO2005014052A1 Radioimmunoconjugates for targeted alpha therapy
02/17/2005WO2005014036A1 Targeted therapeutic vaccine against p-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers
02/17/2005WO2005014017A1 Medicinal composition for treating cancer
02/17/2005WO2005014011A1 Use of smad 7 antisense oligonucleotides (odn) for the treatment of diseases mediated by the nuclear transcription factor nf-kb
02/17/2005WO2005014006A1 Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
02/17/2005WO2005014004A1 Combinations comprising staurosporines
02/17/2005WO2005013986A1 Pyridylpyrrole derivatives active as kinase inhibitors
02/17/2005WO2005013982A1 Aminotriazole compounds useful as inhibitors of protein kinases
02/17/2005WO2005013966A1 Macrophage activation inhibitor
02/17/2005WO2005013951A2 Pharmaceutical compositions for preventing breast and ovarian cancer
02/17/2005WO2005013938A1 Process for producing drug ultramicroparticle and apparatus therefor
02/17/2005WO2005013899A2 Compositions and methods for the therapy and diagnosis of lung cancer
02/17/2005WO2005013691A1 Use of boranocarbonates for the therapeutic delivery of carbon monoxide
02/17/2005WO2005000266A3 Liposomal formulations comprising a combination of two or more active agents
02/17/2005WO2004103358A3 Combination of histone deacetylase inhibitors with chemotherapeutic agents
02/17/2005WO2004101803A3 Process for producing anticancer agent ll-d45042
02/17/2005WO2004094386A8 Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b)
02/17/2005WO2004093781A3 Podophyllotoxin derivatives as igf-1r inhibitors
02/17/2005WO2004070050A3 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors
02/17/2005WO2004069991A3 Oligomeric compounds for the modulation of survivin expression
02/17/2005WO2004005457A3 Tfc/ beta-catenin regulated genes for treating cancer
02/17/2005WO2003104412A3 Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects
02/17/2005WO2003099192A8 Bis-aromatic alkanols
02/17/2005WO2003080568A3 Probucol derivatives
02/17/2005WO2003070910A3 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
02/17/2005WO2003050258A3 Endogenous retrovirus polypeptides linked to oncogenic transformation
02/17/2005WO2003025131A3 Protein modification and maintenance molecules
02/17/2005WO2002074913A3 Nucleic acid-associated proteins
02/17/2005US20050039232 DNA molecules and polypeptides of Pseudomonas syringae Hrp pathogenicity island and their uses
02/17/2005US20050038505 Drug-delivery endovascular stent and method of forming the same
02/17/2005US20050038249 metal complexes used as prodrugs that may be activated under hypoxic conditions by enzymes or by radiotherapy for treatment of cancer
02/17/2005US20050038248 Chemotherapeutic agents
02/17/2005US20050038239 Locked nucleic acid conjugate for use in treatment of cell proliferative disorders
02/17/2005US20050038119 for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion
02/17/2005US20050038113 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
02/17/2005US20050038112 prevention, control and treatment of cancer; leukemia
02/17/2005US20050038111 4'-cyano- alpha ', alpha ', alpha '-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide; anti-oestrogen (eg, tamoxifen citrate) and/or an aromatase inhibitor (eg, anastrozole); preventing side effect; bioavailability; storage stability; prostate cancer
02/17/2005US20050038105 non-peptide molecules, comprising side chains of amino acids, capable of adopting a helicoidal structure independent of the primary structure of the molecules; mimics active natural helices
02/17/2005US20050038095 Azolylbenzamides and analogues and their use for treating osteoporosis
02/17/2005US20050038090 cytotoxic agents; made by fermentation of Streptomyces sparsogenes
02/17/2005US20050038080 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
02/17/2005US20050038074 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide; antiproliferative and -carcinogenic agents
02/17/2005US20050038072 Nitrogeneous cyclic ketone derivative, process for producing the same, and use
02/17/2005US20050038069 Tumor necrosis factor antagonist; antiinflammatory agents; such as 2-Cyclopropyl-4-(3,5-dimethyl-4-pyridylmethoxy)-7-methoxy-3H-benzimidazole
02/17/2005US20050038061 6-Aminomorphinane derivatives, method for production and use thereof
02/17/2005US20050038048 Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
02/17/2005US20050038045 A2B adenosine receptor antagonists
02/17/2005US20050038031 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
02/17/2005US20050038025 Thioarabinofuranosyl compounds and use thereof
02/17/2005US20050038023 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease
02/17/2005US20050038022 Using a benzimidazole carbamate compound in lipid carrier; antitumor agents
02/17/2005US20050038014 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
02/17/2005US20050038012 use in improvement of gastrointestinal blood flow, in treatment of hypertension and in treatment and prophylaxis of cardiac damages induced by adriamycin and comparable anti-cancer drugs
02/17/2005US20050038010 Substituted heterocyclic compounds and methods of use
02/17/2005US20050037999 Antiproliferative agents
02/17/2005US20050037995 Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
02/17/2005US20050037994 Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same
02/17/2005US20050037990 Disubstituted 7,9-guanines halides as telomerase inhibitors
02/17/2005US20050037984 Administering protein kinase C activator
02/17/2005US20050037973 Compounds and methods for cancer therapy
02/17/2005US20050037971 Use of hepcidin as a regulator of iron homeostasis
02/17/2005US20050037949 Mannose binding lectin and uses thereof
02/17/2005US20050037464 Prokineticin polypeptides, related compositions and methods
02/17/2005US20050037462 Expression vector comprising nucleotide sequences coding g protein for use in generating immunoglobulins for use in prevention, treatment and diagnosis of cell proliferative disorders
02/17/2005US20050037445 analyzing molecules expressed on the cell surface of cancer cells and comparing to nonmalignant cells; screening for cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer
02/17/2005US20050037419 Compositions and methods relating to lung specific genes and proteins
02/17/2005US20050037404 Methods of modulating drug clearance mechanisms by altering SXR activity
02/17/2005US20050037376 Sulfatase polypeptide for use in treatment and prevention of microbial infection, cell proliferative, neurodegenerative and cardiovascular disorders
02/17/2005US20050037347 Novel cancer-associated genes
02/17/2005US20050037345 Gene with polynucleopotide codes with polypeptide with amino acid sequences for domains and molecular hybridization for gene expression and cancer
02/17/2005US20050037097 Pyruvate enriched onion extract
02/17/2005US20050037096 Dispersed solid-containing complex carbohydrate
02/17/2005US20050037061 Remedies for mammary cancer
02/17/2005US20050037049 use of benzyl ester of hyaluronic acid and/or derivatives, in association with other biopolymers and antitumor agents to fill cavities when the tumor have been surgically removed
02/17/2005US20050037024 Matrix metalloprotease inhibitor
02/17/2005US20050037010 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
02/17/2005US20050037009 Methods and reagents for protease inhibition
02/17/2005US20050037005 5c8 Antigen
02/17/2005US20050036987 Suicide gene-containing strains of bacteria, fungi, and protists; tumor specific shigella species
02/17/2005US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
02/17/2005US20050035267 Furnace mount and method of installation
02/17/2005US20050035266 Furnace Mount and Method of Installation